Han Xiaoyu, Wang Wei, Shen Zengli, Lv Lisong, Lin Bingyuan, Ren Haiyong, Liu Yiyang, Guo Qiaofeng, Kai Huang, Wang Xiang
Tongde Hospital of Zhejiang Province, Hangzhou, China.
Front Cell Infect Microbiol. 2025 Feb 28;15:1529692. doi: 10.3389/fcimb.2025.1529692. eCollection 2025.
This study aimed to evaluate the effectiveness of intravenous versus oral antibiotic treatments in managing bone infections, particularly osteomyelitis, using a rat tibial infection model.
A tibial bone infection model was established in twelve-week-old Wistar rats via injection of at a cortical defect site. After six weeks, rats were treated with vancomycin (intravenous), cefazolin (intravenous), ciprofloxacin (oral), or ciprofloxacin combined with rifampin (oral). Microbial analysis, blood analysis for pro-inflammatory cytokines, micro-computed tomography (μCT), histological analysis, and osteoclast activity were used to assess the efficacy of each treatment.
Blood analysis showed significant reductions in white blood cell count and pro-inflammatory cytokines in the intravenous treatment groups, especially with vancomycin. μCT imaging revealed better preservation of bone structure in intravenous treatment groups, while oral treatments resulted in more pronounced structural deterioration. Microbial analysis confirmed a lower bacterial load in the intravenous groups, particularly vancomycin, compared to oral treatments. Histological analysis revealed reduced inflammation, lower fibrosis, and minimal bacterial presence in intravenous groups. Osteoclast activity was notably reduced in the vancomycin and cefazolin groups, indicating better control of bone resorption.
Intravenous administration of vancomycin demonstrated superior efficacy in controlling bone infection, reducing inflammation, and preserving bone structure compared to oral treatments. While ciprofloxacin and the ciprofloxacin-rifampin combination showed some efficacy, they were less effective than intravenous vancomycin, likely due to lower bioavailability and insufficient drug penetration in bone tissue.
本研究旨在使用大鼠胫骨感染模型评估静脉注射与口服抗生素治疗骨感染(尤其是骨髓炎)的有效性。
通过在12周龄Wistar大鼠的皮质缺损部位注射,建立胫骨骨感染模型。六周后,大鼠接受万古霉素(静脉注射)、头孢唑林(静脉注射)、环丙沙星(口服)或环丙沙星联合利福平(口服)治疗。采用微生物分析、促炎细胞因子血液分析、微型计算机断层扫描(μCT)、组织学分析和破骨细胞活性评估每种治疗方法的疗效。
血液分析显示,静脉治疗组的白细胞计数和促炎细胞因子显著降低,尤其是使用万古霉素的组。μCT成像显示静脉治疗组的骨结构保存更好,而口服治疗导致更明显的结构恶化。微生物分析证实,与口服治疗相比,静脉组的细菌载量更低,尤其是万古霉素组。组织学分析显示静脉组炎症减轻、纤维化程度降低且细菌存在极少。万古霉素和头孢唑林组的破骨细胞活性显著降低,表明对骨吸收的控制更好。
与口服治疗相比,静脉注射万古霉素在控制骨感染、减轻炎症和保存骨结构方面显示出更高的疗效。虽然环丙沙星和环丙沙星-利福平联合用药显示出一定疗效,但它们的效果不如静脉注射万古霉素,可能是由于生物利用度较低以及药物在骨组织中的渗透不足。